Welcome to our dedicated page for Hologic SEC filings (Ticker: HOLX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hologic, Inc. filings document the company’s transition from a Nasdaq-listed public issuer to a private company after its completed acquisition by funds managed by Blackstone and TPG. The record includes Form 25 notice for removal of Hologic common stock from Nasdaq listing and Form 15 certification to terminate registration or suspend Exchange Act reporting duties for its common stock.
Related 8-K disclosures cover material events, merger-related agreements and shareholder voting matters, capital-structure disclosures, governance and compensation arrangements, operating results, and clinical or regulatory developments tied to Hologic’s women’s health medical-technology business.
HOLOGIC INC director Charles J. Dockendorff disposed of all his company equity in connection with the company’s merger into Hopper Parent Inc. On the merger’s effective date, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right worth up to $3.00 in cash when and if payable. All reported non-qualified stock options and common shares, including those held through a revocable trust, were surrendered to the issuer, leaving Dockendorff with no direct or indirect beneficial ownership of Hologic common stock.
Hologic Inc.’s Principal Accounting Officer, Benjamin Jordan Cohn, reported the cash-out and cancellation of his equity awards in connection with the company’s merger. Multiple non-qualified stock options and 17,964 shares of common stock were disposed of back to the issuer.
Footnotes explain that, at the effective time of the merger, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right worth up to an additional $3.00 in cash per share. Time-vesting restricted stock units and performance stock units held by Cohn were similarly converted into rights to receive this merger consideration, and as a result he no longer beneficially owns any Hologic common stock.
Hologic Inc. filed a Form 25 notifying the Nasdaq Stock Market LLC of the removal/withdrawal of its Common Stock from listing and registration. The notification is executed by Nasdaq (Commission File Number 001-36214) and cites compliance with 17 CFR 240.12d2-2 rules.
Hologic, Inc. has completed its acquisition by funds managed by Blackstone and TPG, becoming a wholly owned subsidiary of Hopper Parent Inc. in a cash deal valuing the company at approximately $17.3 billion.
At closing, each share of Hologic common stock was converted into the right to receive $76.00 in cash plus one contingent value right (CVR) that may pay up to an additional $3.00 per share based on future Breast Health revenue milestones. The company is redeeming all $400 million of its 4.625% 2028 notes and all $950 million of its 3.250% 2029 notes at par plus accrued interest, terminating related credit facilities, and delisting its common stock from Nasdaq. Longtime CEO Stephen MacMillan resigned and José (Joe) E. Almeida was appointed Chief Executive Officer, as Hologic transitions to private ownership under Blackstone and TPG.
Hologic, Inc. announced that longtime Chairman, President and CEO Steve MacMillan will retire immediately after the closing of its go‑private merger with affiliates of funds managed by Blackstone and TPG. His departure is explicitly contingent upon, and effective as of, the transaction’s closing.
The company stated it has received all regulatory approvals necessary to complete the merger, which is expected to close on or about April 7, 2026, subject to customary conditions. Over MacMillan’s more than 12 years at Hologic, revenue increased 65%, non‑GAAP earnings per share rose 184%, the share price gained 241%, and the workforce grew by more than 1,500 employees.
Hologic’s next CEO is expected to be announced when the transaction closes. The company also reiterated forward‑looking statement cautions, highlighting risks that could still affect the merger’s completion and post‑closing outcomes, including for holders of contingent value rights (CVRs).
The Vanguard Group filed Amendment No. 12 to Schedule 13G/A reporting 0 shares of Hologic Inc Common Stock. The filing states that, following an internal realignment effective January 12, 2026, certain subsidiaries and business divisions will report beneficial ownership separately in reliance on SEC Release No. 34-39538.
The Vanguard Group confirms it holds 0 shares and 0% of the class, and that no single outside person is known to hold more than 5% of the securities reported. The form is signed by Ashley Grim, Head of Global Fund Administration.
Hologic Inc. General Counsel Anne M. Liddy reported a small share disposition related to taxes, not an open-market sale. On the transaction date, 185 shares of common stock were withheld at $75.36 per share to cover tax obligations from vested restricted stock units. After this tax-withholding disposition, she directly owned 28,052 Hologic shares.
Hologic Inc. director Amy McBride reported an acquisition of 3,190 shares of common stock in the form of restricted stock units. These units vest on the date of the 2027 Annual Meeting of Stockholders and will be settled one-for-one in common shares, bringing her direct holdings to 25,784 shares.